Full Press Release Details
Aurora Commences Cannabis Oil Sales to
High-Margin Derivative
Products Accelerating European Revenue Growth
EDMONTON, March 11, 2019 /CNW/ - Aurora
Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) today announced
that it has commenced sales of cannabis oils to German pharmacies following receipt of all necessary approvals from the Canadian
and German regulatory authorities. Pedanios 5/1 drops have become the first extract derived oil product compliant with the German
monograph for in-pharmacy preparation.
Aurora is the medical cannabis market leader
in Germany. The Company has supplied the German market with dried cannabis flower via Aurora Deutschland (formerly Pedanios) since
December 2015, and with Canadian-grown Aurora products since September 2017. Aurora has established a strong brand as a trusted
supplier among prescribing physicians, dispensing pharmacies, and German patients. As one of few companies able to sell oils
in this rapidly growing market, Aurora is well positioned to establish brand leadership in the European derivatives market.
"Having established early mover advantage
in selling cannabis oils in Germany, we are exceptionally positioned to extend our market leadership and accelerate growth of our
European operations," said Neil Belot, Chief Global Business Development Officer. "As our global production
capacity continues to ramp up, we are able to strategically allocate more product from our EU GMP certified cultivation facilities
to this higher margin market that continues to be significantly undersupplied."
Headquartered in Edmonton, Alberta, Canada
with funded capacity in excess of 500,000 kg per annum and sales and operations in 24 countries across five continents, Aurora
is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across
every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis
and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora
has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate
leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale
production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are
designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.
Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf
Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland have achieved this level of certification.
In addition to the Company's rapid organic
growth and strong execution on strategic M&A, which to date includes 16 wholly owned subsidiary companies - MedReleaf,
CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,
CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs and Whistler - Aurora is
distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established
strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber
Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium
Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ)
and High Tide Inc. (CSE:HITI).
Aurora's Common Shares trade on the TSX and
NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit
our investor website, investor.auroramj.com
Neither the TSX, NYSE nor their Regulation
Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing
certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may", "will",
"potential", "proposed" and other similar words, or statements that certain events or conditions "may"
or "will" occur and include, but are not limited to the variety of cannabis products that Aurora will supply to the German
medical market and Aurora's ability to establish brand leadership in the European derivatives market. These statements are
only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking
statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the
date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual
events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation,
and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as expressly required by applicable law.
View original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-commences-cannabis-oil-sales-to-german-pharmacies-300809723.html
SOURCE Aurora Cannabis Inc.
View original content to download multimedia:
For further information: For Media: Heather MacGregor, +1.416.509.5416,
heather.macgregor@auroramj.com; For Investors: Marc Lakmaaker, +1.647.269.5523, marc.lakmaaker@auroramj.com; Rob Kelly, +1.647.331.7228,
rob.kelly@auroramj.com; U.S. Investors: Phil Carlson / Elizabeth Barker,KCSA Strategic Communications, Phone: (212) 896-1233 /
(212) 896-1203, Email: pcarlson@kcsa.com / ebarker@kcsa.com
CO: Aurora Cannabis Inc.
CNW 07:00e 11-MAR-19